Glaxo Stems Stock Slide Over Avandia

Medical chief rebuts findings on heart risks; claims comparable to other drugs
By Peter Fearon,  Newser Staff
Posted May 31, 2007 6:44 AM CDT
Glaxo Stems Stock Slide Over Avandia
'

Glaxo shares pulled out of a tailspin after the pharma giant defended its second biggest selling drug, Avandia, against claims that it triggers heart attacks.  A sharply worded letter from the company's chief medical officer on the website of medical journal The Lancet pointed out that the increased incidence of heart attacks among Avandia patients—0.6%—was still very small.

And he said it was comparable to two other "gold standard" medicines used to treat type 2 diabetes. GlaxoSmithKline was up 50 cents in trading yesterday, but only after panic among investors wiped $21 billion off its market cap.The diabetes drug accounts for only 7% of Glaxo's shares, the Telegraph reports, suggesting the dive was an overreaction.  (Read more GlaxoSmithKline stories.)

We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.
Get the news faster.
Tap to install our app.
X
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.

X